ArticleLiver cancer2024

Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study".

Takeshi Hatanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.